CA2315306A1 - Process for the preparation in pure form of the protease activating blood clotting factor vii, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography - Google Patents

Process for the preparation in pure form of the protease activating blood clotting factor vii, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography Download PDF

Info

Publication number
CA2315306A1
CA2315306A1 CA002315306A CA2315306A CA2315306A1 CA 2315306 A1 CA2315306 A1 CA 2315306A1 CA 002315306 A CA002315306 A CA 002315306A CA 2315306 A CA2315306 A CA 2315306A CA 2315306 A1 CA2315306 A1 CA 2315306A1
Authority
CA
Canada
Prior art keywords
protease
proenzyme
preparation
factor vii
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002315306A
Other languages
English (en)
French (fr)
Inventor
Juergen Roemisch
Annette Feussner
Hans-Arnold Stoehr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
Aventis Behring GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Behring GmbH filed Critical Aventis Behring GmbH
Publication of CA2315306A1 publication Critical patent/CA2315306A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
CA002315306A 1999-08-06 2000-08-03 Process for the preparation in pure form of the protease activating blood clotting factor vii, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography Abandoned CA2315306A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937219.5 1999-08-06
DE19937219A DE19937219A1 (de) 1999-08-06 1999-08-06 Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie

Publications (1)

Publication Number Publication Date
CA2315306A1 true CA2315306A1 (en) 2001-02-06

Family

ID=7917489

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002315306A Abandoned CA2315306A1 (en) 1999-08-06 2000-08-03 Process for the preparation in pure form of the protease activating blood clotting factor vii, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography

Country Status (8)

Country Link
US (2) US6677440B1 (https=)
EP (1) EP1074616B1 (https=)
JP (1) JP2001095563A (https=)
KR (1) KR20010049988A (https=)
AT (1) ATE386798T1 (https=)
CA (1) CA2315306A1 (https=)
DE (2) DE19937219A1 (https=)
ES (1) ES2298110T3 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19903693A1 (de) * 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
DE10023923A1 (de) * 1999-06-10 2000-12-14 Aventis Behring Gmbh Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
US7153679B2 (en) 2000-07-26 2006-12-26 Aventis Behring Gmbh Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
ES2257361T3 (es) 2000-07-26 2006-08-01 Zlb Behring Gmbh Mutantes de la proteasa activadora del factor vii y procedimiento de deteccion con anticuerpos especificos.
JP4005338B2 (ja) * 2000-11-29 2007-11-07 ペンタックス株式会社 抗体固相化担体、および、その製造方法
US20020114800A1 (en) 2000-11-29 2002-08-22 Asahi Kogaku Kogyo Kabushiki Kaisha Carrier having immobilized antigens or antibodies and method of manufacturing thereof
DE10148037A1 (de) * 2001-09-28 2003-04-17 Aventis Behring Gmbh Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen
DE10205520A1 (de) 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
AU2003232315A1 (en) * 2002-05-07 2003-11-11 Medical Research Council Sarcosyl buffer and its use for the purification of prion protein
KR100508606B1 (ko) * 2002-11-15 2005-08-17 주식회사 바이오세움 효소 안정화 조성물 및 상기 조성물을 이용한 효소 보관방법
RU2364626C2 (ru) * 2003-03-18 2009-08-20 Ново Нордиск Хелт Кэр Аг Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x
WO2008031020A2 (en) * 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
BRPI0810172A2 (pt) 2007-04-13 2014-10-14 Catalyst Biosciences Inc Polipeptídeos de fator vii modificado e seus usos
JP5119545B2 (ja) * 2007-06-19 2013-01-16 国立大学法人 筑波大学 蛋白質を含む液状組成物中における蛋白質の安定化方法
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
EP2729570B1 (en) 2011-07-04 2017-11-22 Qiagen GmbH Reagent usable for the isolation and/or purification of nucleic acids
GB2504499A (en) * 2012-07-31 2014-02-05 Baxter Healthcare Sa Selective measurement of active human protease coagulation factors
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
DE19903693A1 (de) * 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
DE19937218A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie

Also Published As

Publication number Publication date
ES2298110T3 (es) 2008-05-16
EP1074616B1 (de) 2008-02-20
US6677440B1 (en) 2004-01-13
ATE386798T1 (de) 2008-03-15
DE19937219A1 (de) 2001-02-08
DE50014975D1 (de) 2008-04-03
JP2001095563A (ja) 2001-04-10
EP1074616A1 (de) 2001-02-07
KR20010049988A (ko) 2001-06-15
US20040186277A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
CA2315309A1 (en) Process for the preparation in pure form of the protease activating blood clotting factor vii, its proenzyme or a mixture of both proteins by means of affinity chromatography
US6677440B1 (en) Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography
Peterson et al. Identification of a lysyl residue in antithrombin which is essential for heparin binding.
AU2007209363B2 (en) Purification and use of a factor for supporting wound healing
JP4250769B2 (ja) 高度に精製されたｖＷＦまたは因子ＶＩＩＩ／ｖＷＦ複合体を得る方法
Baglia et al. Localization of the high molecular weight kininogen binding site in the heavy chain of human factor XI to amino acids phenylalanine 56 through serine 86.
CA2009390A1 (en) Viper venom polypeptides and variants
Chang et al. The structural elements of hirudin which bind to the fibrinogen recognition site of thrombin are exclusively located within its acidic C-terminal tail
JP3978258B2 (ja) プロトロンビンおよびトロンビンに結合するペプチド
Kerr [6] The second component of human complement
JPH0676438B2 (ja) 血液から単離された蛋白質、該蛋白質の製造方法および該蛋白質を含有する製薬学的組成物
AU781717B2 (en) Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography
US5688912A (en) Peptide ligands which bind to von willebrand factor
JPS62116600A (ja) 試薬および方法
WO1986000910A1 (en) Immunopurification process
Frost et al. Purification and partial characterization of an ostrich α1-antichymotrypsin-like serum inhibitor
Wu Protein C separation from homologous human blood proteins, Cohn fraction IV-1, using immobilized metal affinity chromatography
Mannhalter 4. Therapy with Plasminogen Concentrates: Preliminary Results and Future Strategies
KR20020081601A (ko) Ｆａｃｔｏｒ Ｘａ 억제 단백질 및 그의 제조방법
JPH04108799A (ja) 血液凝固第８因子結合性ペプチド及びその使用
JPH10179159A (ja) モノクローナル抗体、免疫吸着剤としての使用およびヒトプラスミノーゲンの製造方法
HK1128296A (en) Purification and use of a factor for supporting wound healing

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued